EUR 3.05
(2.35%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 36.2 Million EUR | 1005.25% |
2022 | 3.27 Million EUR | 23.76% |
2021 | 2.64 Million EUR | 13.85% |
2020 | 2.32 Million EUR | -8.5% |
2019 | 2.54 Million EUR | -26.96% |
2018 | 3.47 Million EUR | 3.04% |
2017 | 3.37 Million EUR | -32.27% |
2016 | 4.98 Million EUR | 36.37% |
2015 | 3.65 Million EUR | 31.93% |
2014 | 2.77 Million EUR | 1398.23% |
2013 | 184.93 Thousand EUR | 149.4% |
2012 | 74.15 Thousand EUR | -94.55% |
2011 | 1.36 Million EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 9.28 Million EUR | 0.0% |
2023 FY | 36.2 Million EUR | 1005.25% |
2023 Q4 | 35.77 Million EUR | 0.0% |
2023 Q2 | 2.55 Million EUR | 0.0% |
2022 Q4 | 2.69 Million EUR | 0.0% |
2022 FY | 3.27 Million EUR | 23.76% |
2022 Q2 | 583 Thousand EUR | 0.0% |
2021 Q4 | 569 Thousand EUR | 0.0% |
2021 FY | 2.64 Million EUR | 13.85% |
2021 Q2 | 1.31 Million EUR | 0.0% |
2020 Q4 | 877 Thousand EUR | 0.0% |
2020 Q2 | 1.44 Million EUR | 0.0% |
2020 FY | 2.32 Million EUR | -8.5% |
2019 Q2 | 1.82 Million EUR | 0.0% |
2019 Q4 | 718 Thousand EUR | 0.0% |
2019 FY | 2.54 Million EUR | -26.96% |
2018 Q4 | 1.41 Million EUR | 0.0% |
2018 FY | 3.47 Million EUR | 3.04% |
2018 Q2 | 2.06 Million EUR | 0.0% |
2017 Q2 | 1.88 Million EUR | 0.0% |
2017 FY | 3.37 Million EUR | -32.27% |
2017 Q4 | 1.83 Million EUR | 0.0% |
2016 FY | 4.98 Million EUR | 36.37% |
2016 Q2 | 3.03 Million EUR | 0.0% |
2016 Q4 | 2.38 Million EUR | 0.0% |
2015 Q4 | 2.35 Million EUR | 0.0% |
2015 Q2 | 1.65 Million EUR | 0.0% |
2015 FY | 3.65 Million EUR | 31.93% |
2014 Q4 | 1.77 Million EUR | 0.0% |
2014 FY | 2.77 Million EUR | 1398.23% |
2014 Q2 | 997.39 Thousand EUR | 0.0% |
2013 Q3 | 46.23 Thousand EUR | -93.06% |
2013 Q2 | 666.45 Thousand EUR | 1341.47% |
2013 Q1 | 46.23 Thousand EUR | 0.0% |
2013 FY | 184.93 Thousand EUR | 149.4% |
2013 Q4 | 929.01 Thousand EUR | 1909.38% |
2012 Q3 | 18.53 Thousand EUR | 0.0% |
2012 Q1 | 18.53 Thousand EUR | 0.0% |
2012 Q4 | 46.23 Thousand EUR | 149.4% |
2012 FY | 74.15 Thousand EUR | -94.55% |
2012 Q2 | 18.53 Thousand EUR | 0.0% |
2011 Q3 | 340.07 Thousand EUR | 0.0% |
2011 Q2 | 340.07 Thousand EUR | 0.0% |
2011 Q1 | 340.07 Thousand EUR | 0.0% |
2011 FY | 1.36 Million EUR | 0.0% |
2011 Q4 | 18.53 Thousand EUR | -94.55% |
2010 Q4 | 340.07 Thousand EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ABIONYX Pharma SA | 618 Thousand EUR | -5758.9% |
ABIVAX Société Anonyme | 3.91 Million EUR | -825.089% |
Adocia SA | 1.38 Million EUR | -2514.296% |
Aelis Farma SA | 12.35 Million EUR | -192.992% |
Biophytis S.A. | -803 Thousand EUR | 4609.091% |
Advicenne S.A. | 1.42 Million EUR | -2439.13% |
genOway Société anonyme | 20.1 Million EUR | -80.136% |
IntegraGen SA | 5.01 Million EUR | -621.522% |
Medesis Pharma S.A. | -2.66 Million EUR | 1458.767% |
Neovacs S.A. | 29.31 Thousand EUR | -123417.773% |
NFL Biosciences SA | -56.06 Thousand EUR | 64683.333% |
Plant Advanced Technologies SA | 2.15 Million EUR | -1581.811% |
Quantum Genomics Société Anonyme | -1.41 Million EUR | 2651.137% |
Sensorion SA | 3.78 Million EUR | -855.895% |
Theranexus Société Anonyme | -4.63 Million EUR | 880.565% |
TME Pharma N.V. | -127 Thousand EUR | 28610.236% |
Valbiotis SA | 2.66 Million EUR | -1257.121% |
TheraVet SA | -530.79 Thousand EUR | 6921.453% |
Valerio Therapeutics Société anonyme | 1.26 Million EUR | -2757.774% |
DBV Technologies S.A. | 4.15 Million EUR | -770.47% |
Genfit S.A. | 28.22 Million EUR | -28.288% |
GeNeuro SA | -293.8 Thousand EUR | 12424.03% |
Innate Pharma S.A. | -4.12 Million EUR | 978.622% |
Inventiva S.A. | 17.5 Million EUR | -106.903% |
MaaT Pharma SA | 1.65 Million EUR | -2087.795% |
MedinCell S.A. | 9.28 Million EUR | -289.836% |
OSE Immunotherapeutics SA | 2.22 Million EUR | -1525.864% |
Poxel S.A. | 1000.00 EUR | -3620700.0% |
GenSight Biologics S.A. | 3 Million EUR | -1106.933% |
Transgene SA | -28.4 Million EUR | 227.475% |
Valneva SE | 52.83 Million EUR | 31.472% |